Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Harmony Biosciences Holdings, Inc. (HRMY) Insider Trading Activity
Healthcare • Biotechnology • 246 employees
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Total Value
-$283,203,794.02
Total Shares
-9,172,052
Average Trade Value
-$15,733,544.11
Most Active Insider
Valor Iv Pharma Holdings, Llc
Total Activity: $139,391,500
Largest Single Transaction
$121,210,000
by Valor Iv Pharma Holdings, Llc on Nov 1, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
10% Owner
|
Nov 5, 2024 | 600,000 | $18,181,500 | 6,618,033 (-9.1%) | Sale | |
|
10% Owner
|
Nov 5, 2024 | 600,000 | $18,181,500 | 6,051,120 (-9.9%) | Sale | |
|
10% Owner
|
Nov 1, 2024 | 4,000,000 | $121,210,000 | 7,218,033 (-55.4%) | Sale | |
|
10% Owner
|
Nov 1, 2024 | 4,000,000 | $121,210,000 | 6,651,120 (-60.1%) | Sale | |
|
Chief Commercial Officer
|
Oct 29, 2024 | 21,496 | $515,904 | 21,496 (+100.0%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Oct 29, 2024 | 21,496 | $870,018 | 0 | Sale | |
|
Chief Commercial Officer
|
Oct 3, 2024 | 705 | $25,111 | 0 | Sale | |
|
Chief Commercial Officer
|
Oct 3, 2024 | 35,652 | $1,249,435 | 705 (-5057.0%) | Sale | |
|
Chief Commercial Officer
|
Oct 1, 2024 | 400 | $16,077 | 0 | Sale | |
|
Chief Commercial Officer
|
Oct 1, 2024 | 400 | $9,600 | 400 (+100.0%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Sep 30, 2024 | 32,052 | $1,282,080 | 27,948 (-114.7%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Sep 30, 2024 | 60,000 | $10,000 | 60,000 (+100.0%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Sep 30, 2024 | 60,000 | $10,000 | 60,000 (+100.0%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Sep 30, 2024 | 23,643 | $945,720 | 36,357 (-65.0%) | Payment of Exercise Price | |
|
Chief Commercial Officer
|
Sep 30, 2024 | 35,846 | $860,304 | 35,846 (+100.0%) | Exercise/Conversion | |
|
Chief Commercial Officer
|
Sep 30, 2024 | 35,846 | $1,434,951 | 0 | Sale | |
|
Chief Commercial Officer
|
Sep 27, 2024 | 200 | $8,009 | 0 | Sale | |
|
Chief Commercial Officer
|
Sep 27, 2024 | 200 | $4,800 | 200 (+100.0%) | Exercise/Conversion |